Do statins cause an increase in blood glucose levels?

Yes, Statins Do Increase Blood Sugar

Statins cause a modest but real increase in blood glucose levels and increase the risk of new-onset diabetes, but this effect should not prevent their use in patients who need cardiovascular protection, as the cardiovascular benefits far outweigh the diabetogenic risk. 1, 2

The Evidence on Glycemic Effects

In People Without Diabetes

The most comprehensive 2024 meta-analysis of large-scale randomized trials demonstrates that statins cause:

• Small but consistent increases in blood glucose and HbA1c across all statin types 1
• Increased risk of new-onset diabetes that is dose-dependent, with high-intensity statins (like rosuvastatin 20mg or atorvastatin 80mg) carrying greater risk than moderate-intensity regimens 1
• The effect is most pronounced in people already at high risk for diabetes (those with glucose levels near diagnostic thresholds) 1

The mechanism appears to involve both reduced insulin sensitivity (24% decrease) and reduced insulin secretion (12% decrease) 3. Population-based data from Korea confirms that more adherent and intensive statin use correlates with greater increases in fasting glucose 4.

In People With Existing Diabetes

For patients already diagnosed with diabetes:

• Statins modestly worsen glycemic control, with HbA1c increasing by approximately 0.12% (1.3 mmol/mol) on average 5
• This worsening is most pronounced in the first 1-3 months after starting therapy, particularly with atorvastatin 6
• The effect does not persist long-term in people with known diabetes, likely because their glucose is actively monitored and managed 1

Statin-Specific Differences

Not all statins affect glucose equally:

• High-intensity atorvastatin shows the most pronounced adverse effects on both HbA1c and fasting glucose 7
• Rosuvastatin also demonstrates significant diabetogenic effects 4, 7
• Pitavastatin may actually improve glycemic control in some studies 7
• Pravastatin shows minimal to no significant effect on glucose 4, 8

Clinical Management Algorithm

For Patients Without Diabetes Starting Statins:

1. Do not withhold statins due to diabetes risk—cardiovascular benefits exceed this concern 1, 2
2. Monitor glucose status regularly after initiation, especially in high-risk individuals (prediabetes, obesity, metabolic syndrome) 2
3. Reinforce lifestyle interventions for diabetes prevention (weight loss, exercise) 2
4. Consider moderate-intensity statins over high-intensity when cardiovascular risk allows for flexibility

For Patients With Diabetes on Statins:

1. Continue statin therapy—do not discontinue due to modest glycemic effects 2
2. Anticipate a small HbA1c increase in the first few months, particularly with atorvastatin 6
3. Adjust diabetes medications proactively if needed to maintain glycemic targets
4. The small weight gain (0.3 kg) associated with statins does not explain the glycemic effect 1

Critical Context: Risk-Benefit Balance

The 2024 guideline evidence is unequivocal: the cardiovascular mortality and morbidity benefits of statins dramatically outweigh the diabetes risk 1, 2. This holds true even in primary prevention settings among apparently healthy individuals. The risk of major vascular events following cardiovascular disease far exceeds the risk following a diabetes diagnosis 1.

Common Pitfalls to Avoid

• Do not discontinue statins in patients who develop diabetes or experience glucose increases 2
• Do not avoid statins in prediabetic patients who need cardiovascular protection
• Do not ignore the dose-response relationship—use the lowest effective intensity when appropriate
• Do not fail to monitor—check glucose/HbA1c periodically, especially in the first year after statin initiation in high-risk individuals

The diabetogenic effect is real but manageable, and should be viewed as a known adverse effect requiring monitoring rather than a contraindication to life-saving cardiovascular therapy.